Symbols

TGTX

Tg Therapeutics·NASDAQ

--(--)

TGTX fundamentals

TGTX Q4 2025 Earnings

Tg Therapeutics (TGTX) released its earnings on Feb 26, 2026: revenue was 192.57M (YoY +78.00%), beat estimates; EPS was 0.14 (YoY -6.67%), missed estimates.

Revenue / YoY

192.57M

+78.00%

EPS / YoY

0.14

-6.67%

Report date

Feb 26, 2026

TGTX Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total revenue $616 million, Q4 U.S. sales $183 million (92% YoY growth).
BRIUMVI Momentum: 6-year data shows 90% disability-free patients; subcu trial 75% enrolled for 2026 readout.
Financial Strength: $447 million net income in 2025; $600 million+ balance sheet supports $100M+ buybacks.
Strategic Initiatives: ENHANCE trial for single-dose IV, subcu launch potential 2028, and Azer-cel CAR-T expansion.
2026 Outlook: $825-850 million U.S. BRIUMVI sales guidance; subcu could double addressable market.

Earnings

EPS

Revenue

Revenue & Expenses

TGTX has released its 2025 Q4 earnings report, with revenue of 192.57M, reflecting a YoY change of 78.00%, and net profit of 23.04M, showing a YoY change of -1.26%. The Sankey diagram below clearly presents TGTX's revenue sources and cost distribution.

Key Indicators

Tg Therapeutics (TGTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Tg Therapeutics (TGTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Tg Therapeutics (TGTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Tg Therapeutics (TGTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown